L Number	Hits	Search Text	DB	Time stamp
1	2296	("514/183,252.1").CCLS	USPAT	2004/08/22 13:28
2	1066	("544/358,398").CCLS	USPAT	2004/08/22 13:29
3	0	(("514/183,252.1").CCLS) and LK2	USPAT	2004/08/22 13:29
4	491	(("514/183,252.1").CCLS) and diabetes	USPAT	2004/08/22 13:29
5	53	(("544/358,398").CCLS) and diabetes	USPAT	2004/08/22 13:29
6	7	((("514/183,252.1").CCLS) and diabetes) and (((("544/358,398").CCLS) and diabetes)	USPAT	2004/08/22 13:29

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:13:20 ON 22 AUG 2004

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:13:30 ON 22 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 AUG 2004  HIGHEST RN 729615-76-3
DICTIONARY FILE UPDATES:  21 AUG 2004  HIGHEST RN 729615-76-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\0990015.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss full
FULL SEARCH INITIATED 10:13:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1094 TO ITERATE

100.0% PROCESSED    1094 ITERATIONS                          72 ANSWERS
```

SEARCH TIME: 00.00.01

L2 72 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 10:13:57 ON 22 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Aug 2004 VOL 141 ISS 9
FILE LAST UPDATED: 20 Aug 2004 (20040820/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 40 L2

=> d l3 fbib hitstr abs total

L3 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:726503 CAPLUS
DN 139:349795
TI Structural Identification of Nonvolatile Dimerization Products of Glucosamine by Gas Chromatography-Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, and Nuclear Magnetic Resonance Analysis
AU Jun, Mira; Shao, Yu; Ho, Chi-Tang; Koetter, Uwe; Lech, Stanley
CS Department of Food Science, Rutgers University, New Brunswick, NJ, 08901-8520, USA
SO Journal of Agricultural and Food Chemistry (2003), 51(21), 6340-6346
CODEN: JAFCAU; ISSN: 0021-8561
PB American Chemical Society
DT Journal
LA English
IT **17460-13-8**, Deoxyfructosazine
RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
(structural identification of nonvolatile dimerization products of glucosamine by GC-MS, LC-MS, and NMR)
RN 17460-13-8 CAPLUS
CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The degradation profile of glucosamine bulk form stressed at 100°C for 2 h in an aqueous solution was studied. Column chromatog. of acetylated product mixture led to isolation of two pure compds. and a mixture of at least 3 isomers. 5-(Hydroxymethyl)-2-furaldehyde (5-HMF) and 2-(tetrahydroxybutyl)-5-(3',4'-dihydroxy-1'-trans-butenyl)pyrazine, resp. were identified by utilizing a variety of anal. techniques, such as GC-MS, LC-MS, online UV spectrum, 1H and 13C NMR, and DEPT, as well as 1H-1H COSY. 2-(Tetrahydroxybutyl)-5-(2',3',4'-trihydroxybutyl)pyrazine was also identified, commonly known as deoxyfructosazine. In addition, glucosamine solid dosage form was exposed to 40°C/75% relative humility for 10 wk. Methanol extract of glucosamine solid dosage form was analyzed after acetylation by LC-MS, resulting in degradants. Plus, deoxyfructosazine and 2,5-bis(tetrahydroxybutyl)pyrazine (fructosazine) were also determined Furthermore, the mechanisms of formation of identified degradation products are proposed and briefly discussed.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:193525 CAPLUS
DN 139:224171
TI Reduction mechanism of tetrazolium salt XTT by a glucosamine derivative
AU Shimamura, Tomoko; Takamori, Atsuko; Ukeda, Hiroyuki; Sawamura, Masayoshi
CS Department of Bioresources Science, Faculty of Agriculture, Kochi University, Kochi, 783-8502, Japan
SO Bioscience, Biotechnology, and Biochemistry (2003), 67(2), 295-299
CODEN: BBBIEJ; ISSN: 0916-8451
PB Japan Society for Bioscience, Biotechnology, and Agrochemistry
DT Journal
LA English
IT **17460-13-8**, Deoxyfructosazine
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(reduction mechanism of tetrazolium salt XTT by a glucosamine derivative)
RN 17460-13-8 CAPLUS
CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

g. III (dried at 80°/10-3 mm. over P2O5 and recrystd. from 1:10 H2O-iso-PrOH), m. 161-2°, [α]23D -78° (c 0.6, H2O), Rf 0.42 (8:7:6 IV-iso-AmOH-H2O). To 1.24 g. III in 50 cc. 6% H2O2 was added 2 g. NaOH, the mixture warmed gradually to 80°, treated with 3 cc. perhydrol, heated until the Fehling test was neg. and acidified with 2N HNO3 to give 0.19 g. crystalline precipitate, which in 10 cc. 2N NH4OH after evaporation and treatment with aqueous EtOH and Carboraffin, gave the crystalline NH4 salt, which in 5 cc. 2N NH4OH was acidified with 2N HNO3 to yield 2,5-pyrazine-dicarboxylic acid (V), m. 188-89°; di-Me ester, oil, b. 120-40°/10-3 mm. III (6 g.) in 100 cc. 2N HCl, on hydrogenation at 19.5°/756 mm. with 0.5 g. prehydrogenated PdO, filtration, evaporation with EtOH, dissoln. in 6 cc. H2O and 35 cc. EtOH gave 2.5 g. chromatographically pure 1-amino-1-deoxy-D-fructose-HCl (Va), m. 114-16°, which retained 1/4 mole H2O (even after drying at 20°/12 mm. over P2O5). The mother liquor from Va was evaporated to a sirup which was suspended in 100 cc. 5:5:1:3 AcOEt-IV-ACOH-H2O; 50 cc. was chromatographed on a cellulose powder column using the Fischer-Nebel method. After a forerun of 800 cc. 15 cc. fractions were collected. Fractions 66-100 reduced 1,2-(O2N)2C6H4, and these were rechromatographed. The combined fractions 66-78 yielded a single substance (VI), RVa 1.26 ± 0.05. Fractions 88-100 gave pure Va, and fractions 79-87 gave mixts. of Va and VI. VI in H2O evaporated repeatedly with H2O gave a brown sirup which in 10 cc. H2O with 4-O2NC6H4NHNH2 (VII), AcONa, and AcOH heated 2 hrs. at 90° and, after 14 hrs. at 0°, washing with H2O, and EtOH-Et2O, and boiling several hrs. with H2O, gave from the filtrate 0.25 g. N-acetyl-N'-(p-nitrophenyl)hydrazine, m. 212-13°. The hot-H2O-insol. residue, in 100 cc. EtOH, evaporated to 30 cc. yielded 0.145 g. 3-deoxy-D-erythro-hexose p-nitrophenylosazone, violet, m. 248° (absolute EtOH), identical with the compound prepared from Me 3-deoxy-α-D-arabino-hexoside on heating with dilute H2SO4 at 90°, neutralizing with N NaOH, and treating as above with VII. Va with PhNHNH2 gave 55% D-arabino-hexose phenylosazone. 1-Acetamido-1-deoxy-D-fructose (3 g.) in 4.5 g. Et2NH and 30 cc. MeOH was heated 2 hrs. at 90° under O, cooled, washed with MeOH and cold H2O to give I, N: C(CHROH):CH.N:C(CHROH).CH [R = CH(OH)CH(OH)CH2OH], m. 237° (decomposition) (H2O), Rf (8:7:6 IV-iso-AmOH-H2O) 0.37. I reduced in 2N HCl at room temperature gave 49% Va. Inasmuch as the hydrogenation and hydrolysis of III gave 1 mole each of 1-amino-1-deoxy-D-fructose and 1-amino-1,3-dideoxy-D-erythro-hexulose, the structure of III is putatively CH:N.C(CH2R):CH.N:CCHROH, [R = CH(OH)CH(OH)CH2OH].

```
=> s l3 and hypoglycaemic
L4            0 L3 AND HYPOGLYCAEMIC

=> s l3 and diabetes
L5            4 L3 AND DIABETES

=> s l3 and diabetes I
L6            0 L3 AND DIABETES I

=> s l3 and diabetes II
L7            0 L3 AND DIABETES II

=> s l3 and insuline
L8            0 L3 AND INSULINE

=> d l5 fbib hitstr abs total
```

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:489238 CAPLUS
DN 135:82010
TI Association of deoxyfructosazine and a peroxisome proliferating γ-activated receptor agonist antidiabetic
IN Evers, Michel
PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001047529	A2	20010705	WO 2000-FR3606	20001220
WO 2001047529	A3	20021024		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			FR 1999-16359	A 19991223
FR 2802815	A1	20010629	FR 1999-16359	19991223

IT **17460-13-8**, Deoxyfructosazine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(association of deoxyfructosazine and peroxisome proliferating γ-activated receptor agonist antidiabetic)
RN 17460-13-8 CAPLUS
CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The invention concerns the association of deoxyfructosazine and a peroxisome proliferating γ-activated receptor (PPAR-γ) agonist antidiabetic, pharmaceutical compns. containing the association and their use for preventing and/or treating type 2 **diabetes** and its complications. The dosages for deoxyfructosazine and the PPAR-γ agonist (e.g., troglitazone) can be 50-600 and 200-600 mg/day, resp.

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:489236 CAPLUS

DN 135:82009
TI Association of deoxyfructosazine and a sulfonylurea antidiabetic
IN Evers, Michel
PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001047527	A1	20010705	WO 2000-FR3603	20001220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			FR 1999-16358	A 19991223
FR 2802814	A1	20010629	FR 1999-16358	19991223
FR 2802814	B1	20020222		

IT **17460-13-8**, Deoxyfructosazine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(association of deoxyfructosazine and sulfonylurea antidiabetic)
RN 17460-13-8 CAPLUS
CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The invention concerns the association of deoxyfructosazine and an sulfonylurea antidiabetic, pharmaceutical compns. containing the association and their use for preventing and/or treating type-2 **diabetes** and its complications. The dosages of deoxyfructosazine an sulfonylurea antidiabetic (e.g., glimepiride) can be 50-600, and 0.5-6 mg/day, resp.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:489231 CAPLUS
DN 135:82006
TI Combinations of deoxyfructosazine and an antidiabetic of the biguanide family
IN Evers, Michel

PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001047522	A2	20010705	WO 2000-FR3604	20001220
WO 2001047522	A3	20020404		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			FR 1999-16357	A 19991223
FR 2802813	A1	20010629	FR 1999-16357	19991223

IT **17460-13-8**, Deoxyfructosazine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(combinations of deoxyfructosazine and an antidiabetic of the biguanide family)
RN 17460-13-8 CAPLUS
CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The invention concerns the association of deoxyfructosazine and an antidiabetic of the biguanide family, and pharmaceutical compns. and their use for preventing and/or treating type 2 **diabetes** and its complications.

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:489195 CAPLUS
DN 135:81999
TI Combination of deoxyfructosazine and an antidiabetic inhibiting alpha-glucosidase
IN Evers, Michel
PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DT Patent
LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047468	A2	20010705	WO 2000-FR3605	20001220
	WO 2001047468	A3	20021128		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

				FR 1999-16360	A 19991223
	FR 2802816	A1	20010629	FR 1999-16360	19991223

IT **17460-13-8**, Deoxyfructosazine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(combination of deoxyfructosazine and an antidiabetic inhibiting alpha-glucosidase)

RN 17460-13-8 CAPLUS

CN 1,2,3,4-Butanetetrol, 1-[5-[(2S,3R)-2,3,4-trihydroxybutyl]pyrazinyl]-, (1R,2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The invention concerns the combination of deoxyfructosazine and an antidiabetic inhibitor of glucosidase, pharmaceutical compns. containing said combination, and their use for preventing and/or treating type 2 **diabetes** and its complications.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	223.94	379.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-30.80	-30.80

STN INTERNATIONAL LOGOFF AT 10:16:16 ON 22 AUG 2004